Toheed Kamal, MD
Endocrinology, Diabetes & Metabolism · Northport, ALNPI 1174517536
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 352 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,401 and has fallen 56.9% since, to $604 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 352 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$867
- Corcept Therapeutics$606
- AstraZeneca$424
- Medtronic$295
- Bayer$230
- plus $2K from 33 others
What the payments were for
- Speaking & faculty fees$2875%
- Food & beverage$5,51995%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 98 | $1,278 |
| Sanofi-aventis U.S. LLC | 43 | $867 |
| Corcept Therapeutics | 41 | $606 |
| AstraZeneca | 30 | $424 |
| Medtronic | 8 | $295 |
| Bayer | 14 | $230 |
| Boehringer Ingelheim | 12 | $218 |
| Amgen(2 entities) | 14 | $214 |
| Esperion Therapeutics, Inc. | 11 | $175 |
| Sanofi | 2 | $162 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $116 |
| Amarin Pharma, Inc. | 6 | $112 |
| Xeris Pharmaceuticals, Inc. | 6 | $109 |
| Abbott | 6 | $107 |
| Johnson & Johnson | 7 | $96 |
| Novartis | 4 | $85 |
| Lilly USA, LLC | 6 | $83 |
| BETA Bionics, Inc. | 4 | $81 |
| Merck | 5 | $67 |
| Dexcom, Inc. | 2 | $49 |
| Lantheus Medical Imaging, Inc. | 2 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| GSK | 2 | $37 |
| Impulse Dynamics (USA) Inc. | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Atricure, Inc. | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| AbbVie | 1 | $19 |
| Mannkind Corporation | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Averitas Pharma Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Pfizer | 1 | $14 |
| Cvrx, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$106
How this compares
$5,806 in reported general payments places this provider in the 45th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 283 | $320,377 |
| JardianceEmpagliflozin | 289 | $233,139 |
| Tresiba Flextouch U-100Insulin Degludec | 195 | $178,026 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 80 | $141,061 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 134 | $128,731 |
| RybelsusSemaglutide | 79 | $102,729 |
| FarxigaDapagliflozin Propanediol | 108 | $95,331 |
| MounjaroTirzepatide | 72 | $83,934 |
| Novolog FlexpenInsulin Aspart | 200 | $75,493 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 288 | $68,430 |
| TrulicityDulaglutide | 46 | $63,752 |
| Humalog Kwikpen U-100Insulin Lispro | 150 | $57,786 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 52 | $36,192 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $33,068 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $26,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,278 | $428,922379 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi | $218 | $300,892378 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $83 | $156,668159 claims |
| AstraZenecaFarxiga | $424 | $95,331108 claims |
| MerckJanuvia | $67 | $25,67632 claims |
| Johnson & JohnsonInvokana, Xarelto | $96 | $20,05125 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $867 | $14,79016 claims |
| PfizerEliquis | $14 | $12,01315 claims |
| NovartisEntresto | $85 | $7,35111 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $5,776345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Northport
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
- David BellIrondale$112K
- Bethany JacksonFlorence$90K
- Dwain WoodeHuntsville$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.